王茜博士為國(guó)家級(jí)海外高層次人才青年項(xiàng)目獲得者，將于2025年5月全職加入武漢大學(xué)，任生命科學(xué)學(xué)院教授、高致病性病毒與生物安全全國(guó)重點(diǎn)實(shí)驗(yàn)室教授、泰康生命醫(yī)學(xué)中心教授，博士生導(dǎo)師。王茜博士于2018年獲得清華大學(xué)博士學(xué)位，隨后在哈佛大學(xué) Joseph G. Sodroski 教授實(shí)驗(yàn)室開(kāi)展博士后研究，并在哥倫比亞大學(xué)何大一教授（Dr. David Ho）實(shí)驗(yàn)室擔(dān)任高級(jí)副研究員（Associate Research Scientist）。自2024年5月至2025年4月，任美國(guó)哥倫比亞大學(xué)助理教授（Assistant Professor），并曾榮獲2023年度《麻省理工科技評(píng)論》（MIT Technology Review）“35歲以下科技創(chuàng)新35人（Innovators Under 35）中國(guó)區(qū)入選者”。

聯(lián)合實(shí)驗(yàn)室的另一位導(dǎo)師為劉立鴻博士，國(guó)家級(jí)海外高層次人才青年項(xiàng)目獲得者。劉立鴻博士已于2024年5月全職加入武漢大學(xué)，現(xiàn)任武漢大學(xué)生命科學(xué)學(xué)院教授、高致病性病毒與生物安全全國(guó)重點(diǎn)實(shí)驗(yàn)室教授、泰康生命醫(yī)學(xué)中心教授。劉立鴻博士于2015年在中國(guó)科學(xué)院上海巴斯德研究所獲得博士學(xué)位，隨后在美國(guó)洛克菲勒大學(xué)艾倫·戴蒙德艾滋病研究中心何大一教授（Dr. David Ho）課題組開(kāi)展博士后研究。2021年至2024年，任美國(guó)哥倫比亞大學(xué)助理教授（Assistant Professor）。劉立鴻博士科研成果突出，2025年榮獲首屆Wiley新銳科學(xué)家獎(jiǎng)。

王茜博士與劉立鴻博士在冠狀病毒（包括新冠）和艾滋病研究領(lǐng)域取得了一系列突出成果，分別以第一作者或通訊作者身份在 Nature（6 篇）、Cell、New England Journal of Medicine（NEJM，2 篇）、The Lancet、Immunity、Science Translational Medicine、Cell Host & Microbe（2 篇）、Cell Reports（3 篇）、Cell Reports Medicine（2 篇）、The Lancet Infectious Diseases（4 篇）、Journal of Virology（5 篇）等國(guó)際著名期刊發(fā)表研究論文。兩位學(xué)者的研究成果在學(xué)術(shù)界產(chǎn)生廣泛影響，谷歌學(xué)術(shù)總引用超過(guò) 16,500 次。

聯(lián)合實(shí)驗(yàn)室將聚焦重大傳染性疾病對(duì)公共衛(wèi)生安全的影響，帶領(lǐng)團(tuán)隊(duì)開(kāi)展病毒進(jìn)化、感染機(jī)制及人體體液免疫應(yīng)答等方向的研究，致力于揭示病毒長(zhǎng)期演化與公共健康風(fēng)險(xiǎn)之間的內(nèi)在聯(lián)系。因課題組發(fā)展需要，現(xiàn)誠(chéng)摯歡迎對(duì)相關(guān)研究方向感興趣的有志之士加入我們的聯(lián)合團(tuán)隊(duì)，共同推動(dòng)科學(xué)發(fā)現(xiàn)與技術(shù)轉(zhuǎn)化。

招聘流程及要求

現(xiàn)招聘科研助理和博士后！誠(chéng)摯歡迎感興趣的有志之士加入聯(lián)合團(tuán)隊(duì)，有意者請(qǐng)將以下材料發(fā)送至：llh3411@whu.edu.cn。郵件標(biāo)題請(qǐng)注明“應(yīng)聘崗位名稱+姓名”。初審?fù)ㄟ^(guò)后，將通知安排面試，擇優(yōu)錄取。應(yīng)聘材料將予以保密。

1.個(gè)人簡(jiǎn)歷，包括學(xué)習(xí)工作經(jīng)歷、主要研究方向、代表性論文論著清單、獲獎(jiǎng)情況。

2.學(xué)歷學(xué)位證書(shū)、身份證掃描件。

3. Cover letter: 簡(jiǎn)要介紹既往工作、研究興趣和職業(yè)規(guī)劃。

4.申請(qǐng)人認(rèn)為其他有借鑒意義的材料。

5.兩封推薦信，包括碩士或博士導(dǎo)師推薦信一封。推薦信應(yīng)由推薦人郵箱直接發(fā)出。

科研助理：

1.生物學(xué)相關(guān)專業(yè)本科或碩士，具有良好的英文讀寫(xiě)能力；

2.團(tuán)隊(duì)管理能力；

3.根據(jù)武漢大學(xué)相關(guān)規(guī)定以及個(gè)人工作能力，提供具有競(jìng)爭(zhēng)力的薪酬待遇，具體薪資面談。

博士后：

1.已獲得或即將獲得生命科學(xué)相關(guān)專業(yè)博士學(xué)位，有病毒學(xué)、生物信息學(xué)、免疫學(xué)、疫苗學(xué)、結(jié)構(gòu)生物學(xué)等相關(guān)研究背景者優(yōu)先；

2.具有良好的中英文寫(xiě)作能力，以第一作者身份在國(guó)際權(quán)威期刊發(fā)表過(guò)原創(chuàng)性研究論文；

3.身心健康，為人誠(chéng)信，樂(lè)于團(tuán)隊(duì)協(xié)作，具有獨(dú)立開(kāi)展科研工作的能力。

4.具體待遇一人一議，請(qǐng)參考武漢大學(xué)博士后管理規(guī)定：

https://mp.weixin.qq.com/s/OcpHJtxaGg_wWazeXxlV7Q

該招聘長(zhǎng)期有效，招滿為止。

代表性發(fā)表的論文：（* 第一作者，# 通訊作者）

1.Wang Q, Guo Y, Mellis IA, Wu M, Mohri H, Gherasim C, Valdez R, Purpura LJ, Yin MT, Gordon A, Ho DD. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. Cell Reports. 2025 Apr 8;44(4):115543. doi: 10.1016/j.celrep.2025.115543.

2.Wang Q, Mellis IA, Wu M, Bowen A, Gherasim C, Valdez R, Shah JG, Purpura LJ, Yin MT, Gordon A, Guo Y, Ho DD. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. The Lancet Infectious Diseases 2025 Feb 4:S1473-3099(25)00058-1.

3.Wang Q, Guo Y, Ho J, Ho DD. Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages. New England Journal of Medicine 2024 Nov 14;391(19):1863-1864.

4.Wang Q, Mellis IA, Ho J, Bowen A, Kowalski-Dobson T, Valdez R, Katsamba PS, Wu M, Lee C, Shapiro L, Gordon A, Guo Y, Ho DD, Liu L#. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerging Microbes & Infections 2024 Sep 11:2402880.

5.Wang Q, Mellis IA, Guo Y, Gherasim C, Valdez R, Gordon A, Ho DD, Liu L#. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster. Cell Reports Medicine 2024 Aug 23:101701.

6.Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, Gordon A, Liu L#, Ho DD. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. Cell Host & Microbe 2024 Mar 13;32(3):315-321.e3.

7.Wang Q, Guo Y, Schwanz LT, Mellis IA, Sun Y, Qu Y, Urtecho G, Valdez R, Stoneman E, Gordon A, Wang HH, Ho DD, Liu L#. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1. Emerging Microbes & Infections 2024 Dec;13(1):2359004.

8.Wang Q, Zhang S, Nguyen HT, Sodroski JG. Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells. Journal of Virology 2024 Feb 20;98(2):e0159423.

9.Liu L*,#, Casner RA*, Guo Y*, Wang Q*, Iketani S, Chan JFW, Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L, Ho DD. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity. 2023 Oct 10;56(10):2442-2455.e8.

10.Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L#, Ho DD. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature 2023 Dec;624(7992):639-644.

11.Wang Q, Guo Y, Tam AR, Valdez R, Gordon A, Liu L#, Ho DD. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Reports Medicine 2023 Nov 21;4(11):101258.

12.Wang Q, Bowen A, Ho J, Zhang RM, Valdez R, Stoneman E, Gordon A, Liu L#, Ho DD. SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster. Lancet 2023 Nov 18;402(10415):1827-1828.

13.Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L#, Ho DD. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. The Lancet Infectious Diseases 2023 Oct;23(10):e397-e398.

14.Wang Q, Li Z, Guo Y, Mellis IA, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A, Liu L#, Ho DD. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. iScience 2023 Oct 18;26(11):108254.

15.Zhang Z*, Wang Q*, Nguyen HT, Smith AB, Sodroski JG. Alterations in gp120 Glycans or the gp41 Fusion Peptide-Proximal Region Modulate the Stability of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Pretriggered Conformation. Journal of Virology 2023 Sep 28;97(9):e0059223.

16.Wang Q, Bowen A, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A, Liu L#, Ho DD. SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster. The Lancet Infectious Diseases 2023 May;23(5):527-528.

17.Wang Q, Yeh AY, Guo Y, Mohri H, Yu J, Ho DD, Liu L#. Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2. Emerging Microbes & Infections 2023 May 3:2210237.

18.Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L#, Ho DD. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. New England Journal of Medicine 2023 Feb 9;388(6):567-569.

19.Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L#, Ho DD. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 2023 Jan 19;186(2):279-286.e8.

20.Liu L, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L & Ho DD. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science translational medicine. 2022; 14(646):eabn6859.

21.Iketani S*, Liu L*, Guo Y*, Liu L*, Chan JF*, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z & Ho DD. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 2022; 604(7906):553-6.

22.Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY & Ho DD. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 2022; 602(7898):676-81.

23.Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Liu M, Wang M, Yu J, Sheng Z, Huang Y, Liu L#, Ho DD. Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization. The Lancet Infectious Diseases 2022 Oct 31:S1473-3099(22)00694-6.

24.Wang Q, Iketani S, Li Z, Guo Y, Yeh AY, Liu M, Yu J, Sheng Z, Huang Y, Liu L#, Ho DD. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host & Microbe 2022 Sep 6:S1931-3128(22)00419-X.

25.Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L#, Ho DD. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022 Aug;608(7923):603-608.

26.Wang Q*,#, Anang S*, Iketani S, Guo Y, Liu L, Katsamba PS, Shapiro L, Ho DD, Sodroski JG#. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Reports 2022 Jun 14;39(11):110924.

27.Wang Q, Esnault F, Zhao M, Chiu TJ, Smith AB, Nguyen HT, Sodroski JG. Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can be Minimized by Distant State 1-Stabilizing Changes. Journal of Virology 2022 Mar 15;e0187821.

28.Wang P*, Nair MS*, Liu L*, Iketani S*, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, and Ho DD. Nature 2021; Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature 2021;593, 130-135.

29.Wang Q, Nair MS, Anang S, Zhang S, Nguyen H, Huang Y, Liu L, Ho DD, Sodroski JG. Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. iScience 2021; Nov 19;24(11):103393.

30.Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020; 584(7821): 450-456.

31.Wang Q, Ma B, Liang Q, Zhu A, Wang H, Fu L, Han X, Shi X, Xiang Y, Shang H and Zhang L. Stabilized diverse HIV-1 envelope trimers for vaccine design. Emerging Microbes & Infections 2020 Dec;9(1):775-786.

32.Wang Q, Finzi A and Sodroski JG. The Conformational States of the HIV-1 Envelope Glycoproteins. Trends in Microbiology 2020 Aug;28(8):655-667.

33.Liu L, Wang P*, Nair MS*, Yu J*, Rapp M*, Wang Q*, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020 Aug;584(7821):450-456.

文章發(fā)表情況詳見(jiàn)：

1.https://scholar.google.com/citations?hl=en&user=p3szl5IAAAAJ

2.https://scholar.google.com/citations?user=VLggvyoAAAAJ&hl=en

為防止簡(jiǎn)歷投遞丟失請(qǐng)抄送一份至：boshijob@126.com（郵件標(biāo)題格式：應(yīng)聘職位名稱+姓名+學(xué)歷+專業(yè)+中國(guó)博士人才網(wǎng)）